Our early-phase formulation development services help solve oral bioavailability challenges encountered at both preclinical and clinical stages. We are able to address issues such as incomplete dissolution, low solubility, low oral bioavailability and food effects, through in-depth molecular characterization and various solubilization/enabling technologies.
Our services for discovery phase formulation development are tailored to address specific challenges which arise due to higher systemic exposure requirements for toxicology studies, non-feasibility of high doses/strengths, studies in varied animal species, emesis, compound limitation, liquid dosage form requirement, precipitation of compound at absorption site and more.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.